Revance downgraded to Hold from Buy at Needham
PremiumThe FlyRevance downgraded to Hold from Buy at Needham
1M ago
Revance downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
Revance downgraded to Neutral from Overweight at Piper Sandler
1M ago
Revance downgraded to Market Perform from Outperform at William Blair
Premium
The Fly
Revance downgraded to Market Perform from Outperform at William Blair
1M ago
Revance Therapeutics Reports Surge in Aesthetic Portfolio Growth
PremiumCompany AnnouncementsRevance Therapeutics Reports Surge in Aesthetic Portfolio Growth
1M ago
Revance price target lowered to $6 from $11 at Piper Sandler
Premium
The Fly
Revance price target lowered to $6 from $11 at Piper Sandler
1M ago
Revance backs FY24 product revenue view at least $280M
Premium
The Fly
Revance backs FY24 product revenue view at least $280M
1M ago
Revance price target lowered to $8 from $9 at Mizuho
PremiumThe FlyRevance price target lowered to $8 from $9 at Mizuho
4M ago
Revance price target lowered to $11 from $12 at H.C. Wainwright
Premium
The Fly
Revance price target lowered to $11 from $12 at H.C. Wainwright
4M ago
Revance Therapeutics Launches DAXXIFY® for Cervical Dystonia
Premium
Company Announcements
Revance Therapeutics Launches DAXXIFY® for Cervical Dystonia
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100